Reunited, and it feels so good! Regulatory professionals from all over the world congregated once again for RAPS Convergence 2022, the largest annual regulatory-focused global event, held this year in Phoenix, Arizona, from September 11th-13th. 1,700 life science professionals gathered in person for the first time since 2019, filling the halls of the Phoenix Convention Center with 196 speakers across 250 sessions spanning topics on medical devices, IVDR, life science translations and global regulations.
And that’s a RAP(S)
It was exciting to meet face-to-face with industry leaders once again and be able to talk about the regulatory and compliance issues they are facing. This year was unique with a reoccurring topic of worry; new 2024 EU MDR certification requirements and a fast-approaching due date. With numerous seminars touching on this topic, it was clearly something looming on many regulatory members’ minds. Equipped with the new tools and knowledge they needed to help their organizations meet compliance, members were aware they had one specific task left, EU MDR language translations.
Luckily, after speaking with all the guests that stopped by our booth, a level of relief could be felt when informing them of the role Morningside can play in helping meet the strict EU MDR and labeling requirements. Once done updating and meeting compliance, they can rely on Morningside to translate their materials to meet the updated EU language requirements before the deadline.
Everyone we spoke with was reassured that they could trust in the quality of our translations, knowing Morningside is ISO 9001:2015, 13485:2016, and 7100:2015 certified, ensuring high-quality translations every time!
If you want more Life Science Language Services after RAPS Convergence 2022
If you didn’t get a chance to stop by our booth to learn about our life science language services, our experts are still available for consultations. Suppose you did get to stop by to speak with our Morningside experts. In that case, we know you walked away with the information you need to help solve your business’ language solution needs. Still, we are always available for any new or arising questions.
About Morningside
Morningside, A Questel Company equips the world’s leading life sciences organizations with a full suite of end-to-end language solutions for their regulatory, clinical, commercial and patent needs. With over 4,000 clients in 55 countries, we’re globally recognized for our life science expertise and technology innovation across pharma, biotech, medical devices, and healthcare. Our life sciences translation services ensure your products and ideas seamlessly reach new markets and comply with all regulatory and cultural requirements through every stage of the product lifecycle — from patent to post-market.
We work exclusively with qualified subject matter experts (SMEs) is just part of our unwavering commitment to quality. Morningside employs ISO 9001, 13485, and 17100-compliant processes and controls and a 3-tier linguistic review process. As an added step to mitigate risk, our proprietary algorithm, the Quality Reliability Indicator (QRI), monitors projects, preemptively identifies areas of potential risk and prevents quality issues before they happen to ensure a reliable and repeatable outcome.
If you want to start a project today, please get in touch with us or schedule a meeting with one of our representatives.
Bryan Sulicki, Life Science Business Development Associate at Morningside, a Questel Company, is responsible for supporting the company’s life science translation goals and maintaining strong relationships with leading pharmaceutical and medical device companies. Bryan advises life science organizations on best translation practices with workflows that cut cost, boost quality, and reduce time. He strongly focuses on global marketing, regulatory, and clinical documentation that ensures compliance in the pharmaceutical and medical device marketplaces.